MGMT and central nervous system cancer: Since it is also capable of passing the blood–tumor barrier in human glioma [146] and its activity is observable in MGMT-methylated and -unmethylated tumors [148], combination therapy has been explored in several phase I and II trials but failed to improve survival outcome [148–152].